Hard to Treat Diseases Inc.

OTC: HTDS · Healthcare · Biotechnology

PublicHQ Clearwater, Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 55

v0.1 · 5/100 weight · pillars only

↑ listing tenure, market scale · ↓ market scale, listing tenure

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

—

as of 2026-09-01

Market cap

$109.6k

as of 2026-09-01

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Hard to Treat Diseases Inc.’s financial profile?

Hard to Treat Diseases Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

Ocean Biomedical, Inc.——Asep Medical Holdings Inc——Lotus Pharmaceuticals, Inc.——MedSmart Group Inc.——MedGen, Inc.——Akanda Corp.——

Key facts

CEOTerry Yuan

SectorHealthcare

IndustryBiotechnology

HeadquartersClearwater, null

ExchangeOTC: HTDS

Employees—

IPO date1998-09-25

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.